上海凯宝(300039.SZ)：共有92个药品纳入国家医保目录

Core Viewpoint - Shanghai Kaibao (300039.SZ) announced that it and its wholly-owned subsidiary, Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd., have a total of 92 drugs included in the National Medical Insurance Directory, with 50 classified as Category A and 42 as Category B [1] Group 1: Drug Inclusion in National Medical Insurance Directory - The company has three exclusive products (Tanreqing Injection, Tanreqing Capsules, and Qishen Capsules) and one exclusive dosage form (Duo Suo Tea Alkaloid Capsules) continuing in the National Medical Insurance Directory (2025) [1] - The company's products Linggui Zhugan Decoction Granules, Yiguan Decoction Granules, and the subsidiary's Duo Suo Tea Alkaloid Tablets are included in the National Medical Insurance Directory (2025) [1] - The exclusive product Tanreqing Capsules remains in the National Medical Insurance Directory (2025) with a reimbursement standard of 4.09 yuan per (0.4g/piece), valid from January 1, 2026, to December 31, 2027 [1] Group 2: Changes in Drug Status - The subsidiary's products, Compound Robama Tablets and Baldness Pills, have been removed from the National Medical Insurance Directory (2025) [1] - Currently, the removal of the aforementioned products from the insurance directory has no substantial impact on the company's operating performance [1] - Other products' inclusion in the National Medical Insurance Directory (2025) remains unchanged compared to the National Medical Insurance Directory (2024) [1]